Bremelanotide Research
Kingsberg 2019 — RECONNECT Phase 3 Trials
Obstet Gynecol·November 1, 2019
Sheryl A. Kingsberg, Anita H. Clayton, David Portman, Leonard A. Williams, Julie Krop, Robert Jordan, Johna Lucas, James A. Simon
Summary
Both studies demonstrated that bremelanotide significantly improved sexual desire and related distress in premenopausal women with HSDD. Safety profile was favorable.
Study Details
Study Design
Two identical Phase 3 RCTs
Indication
Female HSDD
Intervention
1.75 mg SC
Species
Human
Sample Size
1,247 subjects
Risk of Bias Assessment
Industry-sponsored
Tags
SourceRCTPhase3ReconnectPivotalTier 1